Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.

Autor: Dieci MV; Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy. Electronic address: mariavittoria.%20dieci@unipd.it., Azzarello G; Oncology and Oncologic Hematology, AULSS 3 Serenissima, Mirano Hospital, Mirano (Venice), Italy., Zagonel V; Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Bassan F; Oncology, AULSS 7 Pedemontana, Santorso Hospital and Bassano Hospital, Vicenza, Italy., Gori S; Oncology, IRCCS Ospedale Don Calabria-Sacro Cuore, Negrar di Valpolicella, (Verona), Italy., Aprile G; Department of Oncology, San Bortolo General Hospital, AULSS 8 Berica, Vicenza, Italy., Chiarion-Sileni V; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Lonardi S; Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Oliani C; Oncology, AULSS 5 Polesana, Santa Maria Della Misericordia Hospital, Rovigo, Italy., Zaninelli M; Oncology, AULSS 9 Scaligera, Villafranca Hospital, Villafranca, (VR), Italy., Chiari R; Oncology, AULSS 6 Euganea, South Padova Hospital, Monselice, (PD), Italy., Favaretto A; Department of Oncology, AULSS 2 Marca Trevigiana, Ca'Foncello Hospital, Treviso, Italy., Pavan A; Oncology Department, AULSS 3 Serenissima, Sant'Angelo General Hospital, Mestre and SS Giovanni e Paolo General Hospital, Venezia, Italy., Di Liso E; Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Mioranza E; Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Baldoni A; Oncology and Oncologic Hematology, AULSS 3 Serenissima, Mirano Hospital, Mirano (Venice), Italy., Bergamo F; Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Maruzzo M; Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Ziampiri S; Oncology, AULSS 7 Pedemontana, Santorso Hospital and Bassano Hospital, Vicenza, Italy., Inno A; Oncology, IRCCS Ospedale Don Calabria-Sacro Cuore, Negrar di Valpolicella, (Verona), Italy., Graziani F; Department of Oncology, San Bortolo General Hospital, AULSS 8 Berica, Vicenza, Italy., Sinigaglia G; Oncology, AULSS 5 Polesana, Santa Maria Della Misericordia Hospital, Rovigo, Italy., Celestino M; Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Conte P; Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy., Guarneri V; Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 May; Vol. 167, pp. 81-91. Date of Electronic Publication: 2022 Mar 18.

ACHIEVEMENT OF AMENORRHEA A DESIDERABLE SIDE EFFECT OF BREAST CANCER TREATMENT IN YOUNG PREMENOPAUSAL PATIENTS?

Autor: Baretta, Z, Evangelista, L, Orvieto, E, Lo Mele, M, Ziampiri, S, Artioli, G, Jirillo, A, Ghiotto, C.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3657::8f60261f368d85c2a095dce1d6263ec6
http://hdl.handle.net/11577/3312653

A20 - Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO

Autor: Santini, D., Cremolini, C., Salvatore, L., Lonardi, S., Dell'Aquila, E., Cattaneo, M., Loupakis, F., Rossini, D., Vincenzi, B., Ziampiri, S., Buoro, V., Tamburini, E., Basile, D., Corsi, D.C., Fioroni, I., Masi, G., Borelli, B., Del Re, M., Tonini, G., Falcone, A.

Publikováno v: In Annals of Oncology October 2017 28 Supplement 6:vi9-vi9

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

Autor: Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tomasello G; Department of Oncology, ASST Ospedale di Cremona, Cremona, Italy., Dadduzio V; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy.; Department of Medical Oncology Fondazione Policlinico, Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy., Moretto R; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Schirripa M; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy., Antoniotti C; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Fucà G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bergamo F; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy., Rossini D; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Nichetti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ziampiri S; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy., Ghidini M; Department of Oncology, ASST Ospedale di Cremona, Cremona, Italy., Marmorino F; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Falcone A; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., De Braud F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Loupakis F; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy., Lonardi S; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy.

Publikováno v: ESMO open [ESMO Open] 2017 Aug 10; Vol. 2 (3), pp. e000241. Date of Electronic Publication: 2017 Aug 10 (Print Publication: 2017).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.